The addition of new technical specialists strengthens DNAmic's R&D capabilities and supports the continued development of its human protein-based delivery platform.
DNAmic today announced the expansion of its research and development team with the addition of two new technical specialists, reinforcing the company's scientific capabilities as it advances its proprietary human protein-based delivery platform toward preclinical development. The new team members will contribute across multiple areas of the platform, including nanoparticle engineering, molecular biology, production optimization and experimental validation. Their expertise will support ongoing efforts to further improve the performance, scalability and translational potential of DNAmic's modular delivery technology. The expansion reflects the company's continued growth and its commitment to building a multidisciplinary team capable of addressing the scientific and technical challenges associated with next-generation in vivo gene and cell therapies.
Alfonso Fiz
CEO and CO-Founder DNAmic
As DNAmic continues to expand its activities, the company expects to further strengthen its research organization with additional scientific and technical talent in support of future development programs.
DNAmic is a biotechnology company developing a next-generation delivery platform for in vivo gene and cell therapies. Built entirely from engineered human proteins, the company's proprietary bioND™ platform is designed to overcome the key limitations of current viral and non-viral delivery technologies by combining efficient intracellular delivery, programmable cargo encapsulation, and cell-specific targeting within a single modular system.
info@dnamic.bio
